+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peptide Therapeutics Market Research Report by Technology (Hybrid Phase, Liquid Phase, and Solid Phase), API Type, Drug Class, Application, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4968565
  • Report
  • April 2022
  • Region: Global
  • 208 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AmbioPharm Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novo Nordisk A/S
The Global Peptide Therapeutics Market size was estimated at USD 24,461.45 million in 2020, USD 27,134.60 million in 2021, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.97% to reach USD 45,681.04 million by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Peptide Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Technology, the market was studied across Hybrid Phase, Liquid Phase, and Solid Phase.
  • Based on API Type, the market was studied across CMO and In-house.
  • Based on Drug Class, the market was studied across Calcitonins, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, and Vasopressin.
  • Based on Application, the market was studied across Anti-infective, Cancer, Cardio Vascular Disease Respiratory, Central Nervous System, Dermatology, Gastrointestinal, Metabolic, and Renal.
  • Based on End User, the market was studied across Hospitals, Pharmaceutical Industries, and Research Laboratories.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Peptide Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Peptide Therapeutics Market, including AmbioPharm Inc., Amgen Inc., AstraZeneca PLC, Bachem Holding AG, Bristol-Myers Squibb Company, CordenPharma International, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Hemmo Pharmaceuticals Pvt Ltd., Ipsen S.A., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Pfizer Inc., PolyPeptide Group, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Peptide Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Peptide Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peptide Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Peptide Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Peptide Therapeutics Market?
6. What is the market share of the leading vendors in the Global Peptide Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Peptide Therapeutics Market?
Frequently Asked Questions about the Global Peptide Therapeutics Market

What is the estimated value of the Global Peptide Therapeutics Market?

The Global Peptide Therapeutics Market was estimated to be valued at $24461.5 Million in 2020.

What is the growth rate of the Global Peptide Therapeutics Market?

The growth rate of the Global Peptide Therapeutics Market is 10.9%, with an estimated value of $45681.0 Million by 2026.

What is the forecasted size of the Global Peptide Therapeutics Market?

The Global Peptide Therapeutics Market is estimated to be worth $45681.0 Million by 2026.

Who are the key companies in the Global Peptide Therapeutics Market?

Key companies in the Global Peptide Therapeutics Market include AmbioPharm Inc., Amgen Inc., AstraZeneca PLC, Bachem Holding AG, Bristol, Myers Squibb Company, CordenPharma International, Eli Lilly and Company and La Roche AG.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AmbioPharm Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novo Nordisk A/S

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer, cardiovascular disorders (CVDs) and metabolic disorder
5.1.1.2. Technology advancement and R & D investment in new peptides
5.1.2. Restraints
5.1.2.1. Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides
5.1.3. Opportunities
5.1.3.1. Presence of strong product pipeline portfolio
5.1.3.2. Adoption of new platforms that develop next-generation protein or peptide therapeutics
5.1.4. Challenges
5.1.4.1. Presence of stringent safety regulations
5.2. Cumulative Impact of COVID-19
6. Peptide Therapeutics Market, by Technology
6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase
7. Peptide Therapeutics Market, by API Type
7.1. Introduction
7.2. CMO
7.3. In-house
8. Peptide Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Calcitonins
8.3. Glucagon & Analogs
8.4. Insulins
8.5. Luteinizing Hormone-Releasing Hormone
8.6. Somatostatins
8.7. Vasopressin
9. Peptide Therapeutics Market, by Application
9.1. Introduction
9.2. Anti-infective
9.3. Cancer
9.4. Cardio Vascular Disease Respiratory
9.5. Central Nervous System
9.6. Dermatology
9.7. Gastrointestinal
9.8. Metabolic
9.9. Renal
10. Peptide Therapeutics Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Pharmaceutical Industries
10.4. Research Laboratories
11. Americas Peptide Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Peptide Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
13. Europe, Middle East & Africa Peptide Therapeutics Market
13.1. Introduction
13.2. France
13.3. Germany
13.4. Italy
13.5. Netherlands
13.6. Qatar
13.7. Russia
13.8. Saudi Arabia
13.9. South Africa
13.10. Spain
13.11. United Arab Emirates
13.12. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. AmbioPharm Inc.
15.2. Amgen Inc.
15.3. AstraZeneca PLC
15.4. Bachem Holding AG
15.5. Bristol-Myers Squibb Company
15.6. CordenPharma International
15.7. Eli Lilly and Company
15.8. F. Hoffmann-La Roche AG
15.9. GlaxoSmithKline PLC
15.10. Hemmo Pharmaceuticals Pvt Ltd.
15.11. Ipsen S.A.
15.12. Merck & Co., Inc.
15.13. Novartis International AG
15.14. Novo Nordisk A/S
15.15. Pfizer Inc.
15.16. PolyPeptide Group
15.17. Sanofi S.A.
15.18. Takeda Pharmaceutical Company Limited
15.19. Teva Pharmaceutical Industries Ltd.
15.20. Zealand Pharma A/S
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET: DYNAMICS
FIGURE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (%)
FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2026
FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, 2018-2026 (USD MILLION)
FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, 2018-2026 (USD MILLION)
FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2020 VS 2026 (%)
FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2026
FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, 2018-2026 (USD MILLION)
FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, 2018-2026 (USD MILLION)
FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, 2018-2026 (USD MILLION)
FIGURE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, 2018-2026 (USD MILLION)
FIGURE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, 2018-2026 (USD MILLION)
FIGURE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, 2018-2026 (USD MILLION)
FIGURE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, 2018-2026 (USD MILLION)
FIGURE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, 2018-2026 (USD MILLION)
FIGURE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2026
FIGURE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, 2018-2026 (USD MILLION)
FIGURE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, 2018-2026 (USD MILLION)
FIGURE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, 2018-2026 (USD MILLION)
FIGURE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2026 (USD MILLION)
FIGURE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, 2018-2026 (USD MILLION)
FIGURE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2026 (USD MILLION)
FIGURE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, 2018-2026 (USD MILLION)
FIGURE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, 2018-2026 (USD MILLION)
FIGURE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2026
FIGURE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
FIGURE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, 2018-2026 (USD MILLION)
FIGURE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2026 (USD MILLION)
FIGURE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 61. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 66. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 67. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 68. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 69. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 70. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 71. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 72. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 73. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 74. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 75. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 76. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 77. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 78. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 79. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 80. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 81. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 82. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 83. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 84. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 85. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 86. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 87. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 88. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 89. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 90. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 91. GLOBAL PEPTIDE THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 92. GLOBAL PEPTIDE THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 93. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PEPTIDE THERAPEUTICS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2026 (USD MILLION)
TABLE 5. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY STATE, 2018-2026 (USD MILLION)
TABLE 12. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 16. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY STATE, 2018-2026 (USD MILLION)
TABLE 17. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY REGION, 2018-2026 (USD MILLION)
TABLE 21. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 22. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY STATE, 2018-2026 (USD MILLION)
TABLE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2026 (USD MILLION)
TABLE 26. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 27. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY STATE, 2018-2026 (USD MILLION)
TABLE 28. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY REGION, 2018-2026 (USD MILLION)
TABLE 32. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 33. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY STATE, 2018-2026 (USD MILLION)
TABLE 34. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY REGION, 2018-2026 (USD MILLION)
TABLE 37. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 38. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY STATE, 2018-2026 (USD MILLION)
TABLE 39. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY REGION, 2018-2026 (USD MILLION)
TABLE 42. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 43. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY STATE, 2018-2026 (USD MILLION)
TABLE 44. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY REGION, 2018-2026 (USD MILLION)
TABLE 47. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 48. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY STATE, 2018-2026 (USD MILLION)
TABLE 49. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY REGION, 2018-2026 (USD MILLION)
TABLE 52. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 53. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY STATE, 2018-2026 (USD MILLION)
TABLE 54. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2026 (USD MILLION)
TABLE 57. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 58. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY STATE, 2018-2026 (USD MILLION)
TABLE 59. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2018-2026 (USD MILLION)
TABLE 63. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 64. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY STATE, 2018-2026 (USD MILLION)
TABLE 65. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 67. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2026 (USD MILLION)
TABLE 68. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 69. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY STATE, 2018-2026 (USD MILLION)
TABLE 70. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 72. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY REGION, 2018-2026 (USD MILLION)
TABLE 73. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 74. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY STATE, 2018-2026 (USD MILLION)
TABLE 75. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 77. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2026 (USD MILLION)
TABLE 78. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 79. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY STATE, 2018-2026 (USD MILLION)
TABLE 80. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 82. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2026 (USD MILLION)
TABLE 83. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 84. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY STATE, 2018-2026 (USD MILLION)
TABLE 85. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 87. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 88. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 89. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY STATE, 2018-2026 (USD MILLION)
TABLE 90. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 92. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY REGION, 2018-2026 (USD MILLION)
TABLE 93. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 94. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY STATE, 2018-2026 (USD MILLION)
TABLE 95. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 97. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 98. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 99. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY STATE, 2018-2026 (USD MILLION)
TABLE 100. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 102. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2026 (USD MILLION)
TABLE 103. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2026 (USD MILLION)
TABLE 104. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 105. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2026 (USD MILLION)
TABLE 106. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 108. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 109. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 110. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY STATE, 2018-2026 (USD MILLION)
TABLE 111. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 113. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 114. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 115. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY STATE, 2018-2026 (USD MILLION)
TABLE 116. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 118. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 119. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 120. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 121. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 122. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 123. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 124. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 125. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 126. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 127. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 128. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 129. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 130. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 131. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 132. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 133. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 134. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 135. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 137. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 138. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 139. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 140. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 141. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 142. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 143. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 144. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 145. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 147. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 148. GLOBAL PEPTIDE THERAPEUTICS MARKET: SCORES
TABLE 149. GLOBAL PEPTIDE THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 150. GLOBAL PEPTIDE THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 151. GLOBAL PEPTIDE THERAPEUTICS MARKET: RANKING
TABLE 152. GLOBAL PEPTIDE THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 153. GLOBAL PEPTIDE THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 154. GLOBAL PEPTIDE THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 155. GLOBAL PEPTIDE THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 156. GLOBAL PEPTIDE THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 157. GLOBAL PEPTIDE THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 158. GLOBAL PEPTIDE THERAPEUTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bachem Holding AG
  • Bristol-Myers Squibb Company
  • CordenPharma International
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Hemmo Pharmaceuticals Pvt Ltd.
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • PolyPeptide Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S
Note: Product cover images may vary from those shown

Loading
LOADING...